Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030

Eli Lilly is projected to potentially surpass Berkshire Hathaway's market capitalization within five years, driven by its strong growth in the burgeoning weight management drug market. Lilly's Zepbound (tirzepatide) is a key revenue driver, supported by a promising pipeline including the oral GLP-1 orforglipron and the highly efficacious triple-hormone mimetic retatrutide, which could revolutionize the GLP-1 sector. In contrast, Berkshire Hathaway faces medium-term headwinds from the impending departure of Warren Buffett as CEO and challenges impacting its largest holding, Apple, which is contending with tariffs and AI market competition, potentially dampening Berkshire's performance despite its diversified portfolio.

Analysis

Eli Lilly (LLY), currently valued at an $800 billion market cap, is projected to potentially surpass Berkshire Hathaway's (BRK.A/B) $1 trillion valuation within five years, driven by its dominant position in the rapidly expanding weight management drug market. The company's tirzepatide (Zepbound) is a primary revenue driver, contributing to projected revenue and earnings growth significantly outpacing the pharmaceutical industry average, underpinning a "strongly positive" sentiment for LLY (0.8).

Lilly's robust pipeline further solidifies its medium-term outlook, with orforglipron, a potential oral GLP-1 medication, nearing regulatory approval. Additionally, retatrutide, a triple-hormone mimetic, demonstrated exceptional efficacy in Phase 2 studies, matching bariatric surgery outcomes, and could revolutionize the GLP-1 space if Phase 3 trials are successful. These clinical advancements represent significant future catalysts for share price appreciation.

Conversely, Berkshire Hathaway faces notable headwinds, reflected in its negative per-ticker sentiment (-0.4). The impending departure of Warren Buffett as CEO by year-end introduces leadership uncertainty, requiring new CEO Greg Abel to prove his capabilities. Furthermore, Apple (AAPL), Berkshire's largest holding and over a fifth of its $257.2 billion portfolio, is contending with significant tariffs and competitive disadvantages in the AI market, potentially dampening Berkshire's near-term performance.

While Berkshire Hathaway's diversification and investment philosophy maintain its long-term appeal, its performance through 2030 is expected to be "unimpressive" compared to Lilly's growth trajectory. This divergence suggests LLY is poised for substantial outperformance, although BRK.A/B may still offer value for patient, long-term investors.

Key Decisions for Investors

• Investors should evaluate Eli Lilly's strong growth trajectory in the weight management market and its robust pipeline as a potential outperformer in the medium term.
• Prudent investors should closely watch the impact of Warren Buffett's succession on Berkshire Hathaway's operational performance and monitor Apple's ability to navigate tariff pressures and AI competition.
• While Berkshire Hathaway remains a long-term value proposition due to its diversification, investors seeking medium-term growth may find Eli Lilly's specific catalysts more compelling.